Sarepta Therapeutics, Inc. (SRPT) · Sep 23, 2026 · Material agreement

Sarepta settles ELEVIDYS patent fight for $39M, securing broad no-sue protection

$39M patent settlement — $39.0M payment already accrued; broad ELEVIDYS no-sue protection

Sarepta converts an anticipated ELEVIDYS patent settlement into final protection, paying $39M already reserved while removing a major legal overhang.

Sarepta is rebuilding a commercial-stage rare-disease business around ELEVIDYS and its established PMO therapies after a major safety and regulatory disruption; management’s 2026 plan calls for stabilizing growth while advancing the broader pipeline.

The litigation overhang is now converted into a known cost. Sarepta had already recorded a $39.0 million contingency charge for the anticipated settlement, and the final agreement requires the same $39.0 million lump-sum payment within ten days.

ItemFiling detail
Settlement payment$39.0 million (Item 1.01)
Prior accounting charge$39.0 million contingency charge (Item 1.01)
Payment timingWithin 10 days of September 23, 2026 (Item 1.01)

The important value is not the payment; it is the protection around ELEVIDYS. REGENXBIO and UPenn release existing infringement claims covering Sarepta’s AAVrh74-based products, including ELEVIDYS, and agree not to pursue related claims going forward. 〔0〕 〔1〕

This is partly new, not a surprise settlement. The charge shows Sarepta had already signaled that a deal was likely, so the market should not treat the $39 million as an unexpected hit. The incremental news is the breadth and finality of the covenant not to sue, including protection for the existing ELEVIDYS form and AAVrh74 capsid sequence; the litigations will be disposed of with prejudice. 〔2〕 〔3〕

Bottom line: This removes a meaningful legal uncertainty around Sarepta’s core gene-therapy product at an already-reserved cost. It advances the ELEVIDYS commercialization story modestly rather than changing the company’s financial outlook outright.

What to watch next

Settlement agreement in Q3 2026 Form 10-Q

Original filing on SEC EDGAR

More Sarepta Therapeutics, Inc. news

Sarepta settles ELEVIDYS patent fight for $39M, securing broad no-sue protection | SRPT Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.